(Q38752194)

6 September 2017

Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment (English)

1 reference

6 September 2017

1 reference

Philippe Bernard

1

1 reference

PubMed ID

28247089

6 September 2017

Frank Antonicelli

series ordinal

2

1 reference

6 September 2017

28 February 2017

1 reference

American Journal of Clinical Dermatology

6 September 2017

1 reference

6 September 2017

18

1 reference

6 September 2017

4

1 reference

6 September 2017

513-528

1 reference

https://scigraph.springernature.com/pub.10.1007/s40257-017-0264-2

6 September 2017

0 references

cites work

Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Isolation of complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Development of an ELISA to detect anti-BP180 autoantibodies in bullous pemphigoid and herpes gestationis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Characterization of the anti-BP180 autoantibody reactivity profile and epitope mapping in bullous pemphigoid patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

BP230- and BP180-specific auto-antibodies in bullous pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Increased risk of bullous pemphigoid in male and very old patients: A population-based study on incidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Increasing incidence of bullous pemphigoid in Northern Finland: a retrospective database study in Oulu University Hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Bullous pemphigoid in infancy: Clinical and epidemiologic characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Bullous pemphigoid in infants: characteristics, diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Extensive erosive bullous pemphigoid: an atypical and serious clinical variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Bullous pemphigoid and amyotrophic lateral sclerosis: a new clue for understanding the bullous disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

The association of bullous pemphigoid with cerebrovascular disease and dementia: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

A population-based study of the association between bullous pemphigoid and neurologic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Bullous pemphigoid and comorbidities: a case-control study in Portuguese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Impact of neurological diseases on the prognosis of bullous pemphigoid: A retrospective study of 178 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Distribution of collagen XVII in the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Bullous pemphigoid: from the clinic to the bench.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Drug-induced pemphigoid: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

The associations between bullous pemphigoid and drug use: a UK case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Bullous pemphigoid: associations and management guidelines: facts and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Increased frequency of diabetes mellitus in patients with bullous pemphigoid: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

A review of case-control studies on the risk factors for the development of autoimmune blistering diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

A comparison of oral and topical corticosteroids in patients with bullous pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Prediction of survival for patients with bullous pemphigoid: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Clinical features and practical diagnosis of bullous pemphigoid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

The n- vs. u-serration is a learnable criterion to differentiate pemphigoid from epidermolysis bullosa acquisita in direct immunofluorescence serration pattern analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Comparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Serological diagnosis of autoimmune bullous skin diseases: prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Heterogeneous bullous pemphigoid antibodies: detection and characterization by immunoblotting when absent by indirect immunofluorescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Development of an ELISA for the detection of autoantibodies to BP230.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Prevalence and clinical significance of anti-laminin 332 autoantibodies detected by a novel enzyme-linked immunosorbent assay in mucous membrane pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Profile of autoantibody to basement membrane zone proteins in patients with mucous membrane pemphigoid: long-term follow up and influence of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Epidermolysis bullosa acquisita: ultrastructural and immunological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

From anti-p200 pemphigoid to anti-laminin gamma1 pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Development of a simple enzyme-linked immunosorbent assay for the detection of autoantibodies in anti-p200 pemphigoid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Anti-laminin gamma-1 pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Bullous pemphigoid as pruritus in the elderly: a common presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Mortality rate in bullous pemphigoid: a retrospective monocentric cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

High risk of death in elderly patients with extensive bullous pemphigoid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Interventions for bullous pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Evidence-based management of bullous pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Low-dose methotrexate treatment in elderly patients with bullous pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

A retrospective analysis of patients with bullous pemphigoid treated with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Chlorambucil as a steroid-sparing agent in bullous pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

A randomized controlled trial to compare the safety and effectiveness of doxycycline (200 mg daily) with oral prednisolone (0.5 mg kg(-1) daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyc

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Dapsone as first line therapy for bullous pemphigoid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Topical tacrolimus therapy for localized bullous pemphigoid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Adjuvant treatment of recalcitrant bullous pemphigoid with immunoadsorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

[Efficacy of rituximab in a case of refractory bullous pemphigoid].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: A retrospective study with a 6-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Omalizumab therapy for bullous pemphigoid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Development of bullous pemphigoid during treatment of psoriatic onycho-pachydermo periostitis with ustekinumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Positive Direct Immunofluorescence Is of Better Value than ELISA-BP180 and ELISA-BP230 Values for the Prediction of Relapse after Treatment Cessation in Bullous Pemphigoid: A Retrospective Study of 97 Patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

The Relationship between Neurological Disease and Bullous Pemphigoid: A Population-Based Case–Control Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Autoimmune Bullous Skin Diseases Occurring under Anti-Tumor Necrosis Factor Therapy: Two Case Reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

Evaluation of a New ELISA Assay for Detection of BP230 Autoantibodies in Bullous Pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-017-0264-2

10.1007/S40257-017-0264-2

21 January 2018

Identifiers

DOI

1 reference

PubMed ID

28247089

Dimensions Publication ID

6 September 2017

0 references

1 reference

PubMed ID

28247089